Bichotte Hermelyn, Tapia, Meeks, De Los Santos, Lupardo, Davila, Cunningham, Jensen, Reyes,
Lunsford, Forrest, Simon
MLTSPNSR
Amd §30, add Art 3-A §50, Cannabis L; amd §206, Pub Health L
Relates to the topics of the course required to be taken by practitioners certifying patients as eligible for medical cannabis; establishes the endocannabinoid system awareness program; requires the office of cannabis awareness and the department of health to publish information about the endocannabinoid system awareness program on their websites.
STATE OF NEW YORK
________________________________________________________________________
6709--B
2025-2026 Regular Sessions
IN ASSEMBLY
March 10, 2025
___________
Introduced by M. of A. KELLES, BICHOTTE HERMELYN, TAPIA, MEEKS,
DE LOS SANTOS, LUPARDO, DAVILA, CUNNINGHAM, JENSEN, REYES, LUNSFORD,
FORREST, SIMON -- read once and referred to the Committee on Health --
committee discharged, bill amended, ordered reprinted as amended and
recommitted to said committee -- recommitted to the Committee on
Health in accordance with Assembly Rule 3, sec. 2 -- committee
discharged, bill amended, ordered reprinted as amended and recommitted
to said committee
AN ACT to amend the cannabis law and the public health law, in relation
to the course required to be taken by practitioners certifying
patients as eligible for medical cannabis and establishing the endo-
cannabinoid system awareness program
The People of the State of New York, represented in Senate and Assem-bly, do enact as follows:
1 Section 1. Subdivision 8 of section 30 of the cannabis law, as amended
2 by chapter 544 of the laws of 2025, is amended and a new subdivision 9
3 is added to read as follows:
4 8. (a) Prior to issuing a certification a practitioner must complete
5 appropriate training as determined by the board in regulation; provided,
6 however, that such course shall, at a minimum, meet the requirements of
7 paragraph (c) of this subdivision. For the purposes of this article a
8 person's status as a practitioner is deemed to be a "license" for the
9 purposes of section thirty-three hundred ninety of the public health law
10 and shall be subject to the same revocation process.
11 (b) The office shall approve at least one course for practitioners
12 seeking to certify patients for medical cannabis, which shall be a mini-
13 mum of two hours in duration.
14 (c) The educational content of such course or courses shall include:
15 the pharmacology of cannabis; contraindications; side effects; adverse
16 reactions; overdose prevention; drug interactions; dosing; routes of
EXPLANATION--Matter in italics (underscored) is new; matter in brackets
[] is old law to be omitted.
LBD08994-07-6
A. 6709--B 2
1 administration; risks and benefits; warnings and precautions; abuse and
2 dependence; and such other components as determined by the office.
3 9. The office shall provide information on the office's website on the
4 endocannabinoid system awareness program established pursuant to section
5 fifty of this chapter, including the information and guidance estab-
6 lished pursuant to subdivision two of such section.
7 § 2. The cannabis law is amended by adding a new article 3-A to read
8 as follows:
9 ARTICLE 3-A
10 ENDOCANNABINOID SYSTEM AWARENESS PROGRAM
11 Section 50. Endocannabinoid system awareness program.
12 § 50. Endocannabinoid system awareness program. 1. There is hereby
13 established within the office, in consultation with the department of
14 health, the endocannabinoid system awareness program which shall create
15 educational materials for health care practitioners regarding the endo-
16 cannabinoid system and how it interacts with other bodily systems.
17 2. The executive director, in consultation with the commissioner of
18 health, shall create comprehensive information and guidance regarding
19 the endocannabinoid system and how it interacts with other bodily func-
20 tions. Such information and guidance shall include, but not be limited
21 to, the following topics:
22 (a) the endocannabinoid system;
23 (b) cannabinoids, chronic pain and opioids;
24 (c) pharmacogenetics and cannabis;
25 (d) federal food and drug administration (FDA) approved cannabinoid
26 medications;
27 (e) risks, benefits, and impacts of cannabis consumption on body
28 systems; and
29 (f) interactions of cannabis with other medications.
30 § 3. Section 206 of the public health law is amended by adding a new
31 subdivision 32 to read as follows:
32 32. The commissioner shall:
33 (a) send guidance to health care practitioners on the need to be aware
34 of the endocannabinoid system and how it interacts with other bodily
35 functions; and
36 (b) provide information on the department's website on the endocanna-
37 binoid system awareness program, including the information and guidance
38 established pursuant to subdivision two of section fifty of the cannabis
39 law.
40 § 4. This act shall take effect one year after it shall have become a
41 law. Effective immediately, the addition, amendment and/or repeal of
42 any rule or regulation necessary for the implementation of this act on
43 its effective date are authorized to be made and completed on or before
44 such effective date.
